Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 07:00 ET | Source: Antag Therapeutics

Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will...
April 20, 2026 16:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kailera Therapeutics, Inc. (Nasdaq: KLRA), an advanced clinical-stage biotechnology company, today announced the closing of its initial public offering.
April 16, 2026 19:25 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces Pricing of Initial Public Offering

Kailera Therapeutics, Inc. (Nasdaq: KLRA) today announced the pricing of its initial public offering.
April 15, 2026 15:19 ET | Source: King Faisal Prize

Svetlana Mojsov, one of the Scientists behind Ozempic, and Mathematician Carlos Kenig, who Decoded Laws of Motion, Honored as King Faisal Prize 2026 Laureates

Riyadh, Saudi Arabia, April 15, 2026 (GLOBE NEWSWIRE) -- On the evening of April 15, HRH Prince Turki Alfaisal, Acting Chairman of the Board of Trustees of King Faisal Foundation, and King Faisal...
April 13, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting
April 09, 2026 07:00 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
March 31, 2026 11:02 ET | Source: Serenity Medical

Serenity Medical Receives U.S. FDA HDE Approval of the River™ Stent - the First Venous Stent Approved for Severe, Refractory Idiopathic Intracranial Hypertension (IIH)

Landmark regulatory milestone makes the River stent available for adults with severe IIH – a debilitating, historically undertreated condition – who have failed medical therapy Serenity Medical...
March 26, 2026 16:05 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara...
March 25, 2026 16:53 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
March 19, 2026 16:05 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...